Perrigo’s Outgoing CEO Advocates OTC Switches, Starting With Statins

Some sort of "pharmacy intervention" could aid switches, CEO Hendrickson says; board bloc is still pushing to divest the generic Rx segment but apparent second-quarter sales validation isn't enough to persuade Hendrickson to stay on.

Perrigo Co. PLC CEO John Hendrickson used the pulpit of what was likely his final earnings briefing at the helm of the OTC private label leader to urge FDA and manufacturers to make more Rx drug ingredients available nonprescription.

During Perrigo’s second-quarter earnings briefing on Aug. 10, Hendrickson, who will resign from his post when a successor is appointed, recommended specifically that statins “belong over the counter” through Rx-to-OTC...

Three new drug applications to FDA for a statin OTC switch failed and a fourth proposal stalled before an NDA was submitted (see box).Hendrickson recommended that drug firms look at...

More from Marketing & Advertising

More from Compliance